Search Results

• • 4 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial.

  Authors:Keith J Chappell, Francesca L Mordant, Zheyi Li, Danushka K Wijesundara, Paula Ellenberg, Julia A Lackenby, et al.From:The Lancet Infectious Diseases (Vol. 21, Issue 10) Peer-Reviewed

  Oct. 20211,076 words Article

   Abstract Only

• Persistence of SARS-CoV-2--Specific IgG in Children 6 Months After Infection, Australia.

  Authors:Zheng Quan Toh, Rachel A. Higgins, Lien Anh Ha Do, Karin Rautenbacher, Francesca L. Mordant, Kanta Subbarao, et al.From:Emerging Infectious Diseases (Vol. 27, Issue 8) Peer-Reviewed

  Aug. 20211,573 words Report 1290LThe duration of the humoral immune response in children infected with severe acute respiratory syndrome coronavirus 2 is unknown. We detected specific IgG 6 months after infection in children who were asymptomatic or had...

• Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice.

  Authors:Phillip Pymm, Amy Adair, Li-Jin Chan, James P. Cooney, Francesca L. Mordant, Cody C. Allison, et al.From:Proceedings of the National Academy of Sciences of the United States (Vol. 118, Issue 19) Peer-Reviewed

  May 11, 202112,197 words Report 1560L

   Abstract Only

• Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19

  Authors:Jennifer A. Juno, Hyon-Xhi Tan, Wen Shi Lee, Arnold Reynaldi, Hannah G. Kelly, Kathleen Wragg, et al.From:Nature Medicine (Vol. 26, Issue 9) Peer-Reviewed

  Sept. 20207,739 words Report 1740LThe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has dramatically expedited global vaccine development efforts.sup.1-3, most targeting the viral 'spike' glycoprotein (S). S localizes on the...